Levobetaxolol
Appearance
| Clinical data | |
|---|---|
| Trade names | Betaxon |
| Other names | AL-1577A |
| AHFS/Drugs.com | Micromedex Detailed Consumer Information |
| Routes of administration | Ophthalmic |
| ATC code |
|
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Elimination half-life | 20 hours |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| ChemSpider | |
| UNII | |
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C18H29NO3 |
| Molar mass | 307.434 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Levobetaxolol, sold under the brand name Betaxon, is a medication used to lower the pressure in the eye in treating conditions such as glaucoma.[1] It is used as the salt levobetaxolol hydrochloride.[1] Levobetaxolol is a beta-adrenergic receptor inhibitor (beta blocker).[1]
Medical uses
[edit]Levobetaxolol is indicated for lowering intraocular pressure in people with chronic open-angle glaucoma or ocular hypertension.[1][2]
Contraindications
[edit]Levobetaxolol is contraindicated in people with sinus bradycardia, atrioventricular block, cardiogenic shock, or overt cardiac failure.[1]
History
[edit]Levobetaxolol was developed in the 1980s.[2] It was approved by the US Food and Drug Administration in 2000.[3][4]
References
[edit]- 1 2 3 4 5 6 https://www.accessdata.fda.gov/drugsatfda_docs/label/2000/21114lbl.pdf
- 1 2 Quaranta L, Turano R, Pizzolante T (June 2007). "Levobetaxolol hydrochloride: a review of its pharmacology and use in the treatment of chronic open-angle glaucoma and ocular hypertension". Clinical Ophthalmology. 1 (2): 93–7. PMC 2704505. PMID 19668496.
- ↑ "Drug Approval Package: Betaxon (Levobetaxolol Hydrochloride) Ophthalmic Suspension". U.S. Food and Drug Administration (FDA). Retrieved 9 November 2026.
- ↑ "Betaxon New FDA Drug Approval". CenterWatch. Retrieved 11 April 2019.